Shares of Nevro Corp (NYSE:NVRO) have been given a consensus recommendation of “Hold” by the eleven research firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $99.71.
Several research firms have recently commented on NVRO. Northland Securities reiterated a “buy” rating and set a $96.00 target price on shares of Nevro in a research note on Tuesday, November 7th. ValuEngine cut Nevro from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. Leerink Swann reiterated an “outperform” rating and set a $110.00 target price (up from $105.00) on shares of Nevro in a research note on Tuesday, November 7th. Canaccord Genuity reduced their target price on Nevro from $120.00 to $110.00 and set a “buy” rating for the company in a research note on Tuesday, November 7th. Finally, TheStreet upgraded Nevro from a “d+” rating to a “c-” rating in a research note on Monday, November 6th.
A number of institutional investors and hedge funds have recently made changes to their positions in NVRO. Hershey Trust Co. bought a new position in Nevro during the fourth quarter worth $119,000. Public Employees Retirement Association of Colorado bought a new position in Nevro during the fourth quarter worth $160,000. Ameritas Investment Partners Inc. increased its position in Nevro by 17.3% in the second quarter. Ameritas Investment Partners Inc. now owns 2,432 shares of the medical equipment provider’s stock worth $181,000 after buying an additional 358 shares during the period. PNC Financial Services Group Inc. acquired a new stake in Nevro in the second quarter worth $190,000. Finally, Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Nevro in the third quarter worth $211,000.
Nevro Company Profile
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.